Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Dual endothelin angiotensin receptor antagonists

4 evidence topics · 3 sources

Sparsentan in participants with APOL1 high-risk genotypes: DUPLEX post hoc analysis
SubgroupSparsentan, time-averaged change from baseline in UPCR, % (95% CI)Irbesartan, time-averaged change from baseline in UPCR, % (95% CI)Relative change, % (95% CI)P value
APOL1 high-risk genotypes“−54.3 (−76.6 to −10.9)”View highlighted excerpt for this quote“−33.8 (−71.2 to 52.2)”View highlighted excerpt for this quote“−27.3 (−78.1 to 141.2)”View highlighted excerpt for this quote“0.57”View highlighted excerpt for this quote